The Opportunity Our Model Strategies Research Culture Team Request a Conversation
Home/Strategies/ Growth Equity
1. Growth Equity

Driving the next wave of UK innovation through strategic growth capital.

Long-term capital for the UK's most innovative companies in life sciences, technology and sustainability.

Strategies 1 Growth Equity 2 Infrastructure 3 Private Equity 4 Private Credit 5 Real Estate
Overview

Why now?

The UK growth-stage funding gap remains acute in high-growth sectors. With government support via the Mansion House Compact and British Patient Capital programme, and aligned to UK industrial strategy and Net Zero, our growth equity strategy backs the founders building the next generation of UK champions.

Biotech laboratory — placeholder image
Sub-Strategies

Three sectors.
One growth platform.

Focused exposure to the highest-growth segments of the UK innovation economy — life sciences, technology and sustainability.

Sub-Strategy Purpose
Life Sciences Back UK biotech, drug discovery and health innovators
Technology Scale UK technology leaders across fintech, AI and advanced manufacturing
Sustainability Net Zero and ESG-aligned UK growth companies
The Team

Specialists in UK growth-stage investing.

100 years of combined experience with deep expertise in venture capital, life sciences and sustainable high-growth UK technology.

Fred Rizzo

Head of Growth Equity
  • Senior growth equity investor with deep UK and European experience
  • Former Investment Manager, GIC
  • Track record across technology and consumer growth; co-leads origination and portfolio strategy at PBP

To Be Announced

Growth Equity Partner
  • Senior venture investor — appointment to be announced
  • Currently CIO of a $500m discretionary portfolio with strong track record, including 5x, 2.8x and 2.0x realised exits
  • Previously founder and CEO of a technology business

Hamant Maini

Growth Equity Investor
  • 15 years in private and growth equity investing and operational value creation
  • Track record of leading UK mid-market and growth investments
  • Specialised in complex carve-outs and partnership structures

Violeta Hvamb

Growth Equity Strategic Advisor
  • 20+ years in decarbonisation and healthcare
  • Deep ESG expertise and global transaction experience
  • Proven leadership in scaling investment platforms
Case Studies

Indicative track record.

Selected representative growth equity investments illustrating the team's sector focus and value creation approach.

Technology

Project Quantum

Thesis: Deep tech with first-of-its-kind decomposer network reducing AI computational load.

Value creation: International expansion, strategic partnerships.

22% IRR · 2.5x MOIC
Healthcare

Project Apex

Thesis: Drug discovery business using bi-specific antibody technology.

Value creation: R&D support and global distribution.

20% IRR · 3.0x MOIC
Sustainability

CleanTech UK

Thesis: Net Zero demand for green solutions across UK industry.

Value creation: ESG integration and operational scaling.

19% IRR · 2.6x MOIC
Asset Owner / Investor Value Proposition

Why invest with Point Break?

Access

Proprietary UK growth equity opportunities sourced through deep relationships with founder communities, accelerators and early-stage VCs.

Return Profile

15–20% IRR net target range with MOIC of 2.5–3.0x across the portfolio.

Co-Investment

Significant and comprehensive co-investment opportunity across deployments.

Risk & Governance

Best-in-class risk management frameworks and experience. Sophisticated governance framework across investment committee, independent valuation, audit and ESG.

Get in touch

Discuss the Growth Equity strategy with our team.

Materials and detailed strategy decks are available under NDA. All enquiries are handled personally by a member of the leadership team.

Request a Conversation